Navigation Links
Vermillion Reports First Quarter 2013 Results
Date:5/15/2013

AUSTIN, Texas, May 15, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women's health, reported on its financial results for the first quarter ended March 31, 2013.

Q1 2013 Financial Results
Total revenue in the first quarter of 2013 was $328,000, compared to $312,000 in the same year-ago quarter. First quarter 2013 revenue was comprised of $214,000 in OVA1 product sales and $114,000 in license revenue, as compared to $198,000 of OVA1 product sales and $114,000 in license revenue in the year-ago quarter.

First quarter of 2013 product revenue was derived from 4,274 OVA1 tests performed at the fixed $50 per test as reported by the company's OVA1 marketing partner, Quest Diagnostics. This was an 8% increase from 3,952 OVA1 tests performed at the fixed $50 per test in the year-ago quarter.

The OVA1 product revenue in both periods does not include the additional royalty component of revenue based on 33% of Quest Diagnostics gross margin. Vermillion recognizes this portion of revenue when it is reported by Quest Diagnostics in an annual 'true-up' after the end of the calendar year.  The true-up is based on reimbursed and unreimbursed tests for which Quest Diagnostics considers the payment status as final. For the full year of 2012, the true-up provided $816,000 in revenue to Vermillion or an additional $60 per test.

Total operating expenses in the first quarter of 2013 were $2.9 million as compared to $2.4 million in the same year-ago quarter. The increase is primarily due to one-time items, including costs related to the delayed 2012 annual shareholder meeting held in March 2013, a proxy contest and CEO transition, partially offset by lower sales and marketing costs. Net loss for the first quarter was $2.6 million or $(0.17) per share, as compared to $1.8
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
3. Vermillion Reports First Quarter 2012 Results
4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
5. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
6. Vermillion to Report Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... of the bacterium Caulobacter crescentus , researchers at the ... production factory, making useful proteins that can act as vaccines ... Society for General Microbiology,s meeting at Heriot-Watt University, Edinburgh, today ... bacterium that has a single protein layer on its surface. ...
... REDWOOD CITY, Calif., Sept. 4 Cardica, Inc. (Nasdaq: ... received a notice from the Listing Qualifications Department of The ... be delisted from NASDAQ based upon NASDAQ staff,s determination that ... stockholders, equity requirement for continued listing on the NASDAQ as ...
... BEIJING, Sept. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... products in China, announced today that,the Ministry of Industry ... issued the initial order to Sinovac to purchase H1N1 ... order, Sinovac is,required to complete the production of 3.3 ...
Cached Biology Technology:Cardica Receives NASDAQ Notification of Non-Compliance 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 3
(Date:4/17/2014)... A new modeling study suggests that fish consumption ... infant exposure to long-lived contaminants like persistent organic ... a team of researchers including University of Toronto ... Wania, looks at how different levels of environmental ... behavior of chemicals in the body influenced exposure ...
(Date:4/17/2014)... Kansas State University engineer has developed a patented ... improvised explosive devices. The same technique could help ... Steven M. and Kay L. Theede chair in ... engineering, and his research team have created a ... in car trunks. The distance detection method ...
(Date:4/17/2014)... Several parasites and pathogens that devastate honeybees in Europe, ... Africa, but do not appear to be impacting native ... team of researchers., The invasive pests include including ... East African honeybees appear to be resilient to these ... used to control pests in Europe, Asia and the ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... PHILADELPHIAThe Academy of Natural Sciences today announced the revival ... an early 19th-century nature magazine of which only 13 complete ... Museum of Nature was published privately in London between 1810 ... one or two color plates. In it, Perry set out ...
... NY) Matthew Levy, Ph.D., assistant professor of biochemistry ... has been awarded more than $700,000 by Stand Up ... Levy,s work will focus on creating self-guiding drugs that ... serious or unpleasant side effects of current therapies. Dr. ...
... Just three months after the Euro 5 Norm ... car models, researchers at the Technische Universitaet Muenchen (TUM) ... meeting the more stringent Euro 6 emissions standard. A ... Chair of Internal Combustion Engines has succeeded in reducing ...
Cached Biology News:The Academy of Natural Sciences and Temple Press revive rare natural history work in new book 2Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3
...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... 178-227 of human YBX2. (Note: ... proprietary). ...
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
... Aminopropylsilane is perhaps the ... chemistry for microarray experiments. ... for Microarrays provide a ... for printing PCR products ...
Biology Products: